Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRWTFG)

• Drug Name: A-337 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMRWTFG

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor-associated calcium signal transducer 1 (EPCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vicineum	DMLO0KD	Bladder cancer	2C94	Phase 3	[2]
VB4-845	DMGKRAJ	Head and neck cancer	2D42	Phase 2/3	[3]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[4]
CAR-T Cells targeting EpCAM	DMREQCF	Colon cancer	2B90.Z	Phase 1/2	[5]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
CAR-T cells recognizing EpCAM	DMC7Y5F	Breast cancer	2C60-2C65	Phase 1	[7]
ING-1	DM5WCBM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Citatuzumab bogatox	DMRJF2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
EPCAM-targeted CAR-T cells	DMV6RMB	Gastric adenocarcinoma	2B72	Clinical trial	[10]
IGN-101	DMOG1LX	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[11]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[13]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[14]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[15]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[16]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[17]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[18]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[19]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[20]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[1]
Tumor-associated calcium signal transducer 1 (EPCAM)	TTZ8WH4	EPCAM_HUMAN	Inhibitor	[1]

References

• [1] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [2] Clinical pipeline report, company report or official report of Sesen Bio.
• [3] A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
• [4] ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
• [5] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [6] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [7] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [8] ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
• [9] Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
• [10] ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
• [11] Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65.
• [12] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [13] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [14] Clinical pipeline report, company report or official report of Genmab.
• [15] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [16] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [17] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [18] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [19] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [20] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [21] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.